Literature DB >> 8229758

Mechanism of ochratoxin A-induced reduction of glomerular filtration rate in rats.

M Gekle1, S Silbernagl.   

Abstract

The nephrotoxin ochratoxin A (OTA) causes a reduction of glomerular filtration rate (GFR) and of para-aminohippuric acid (PAH) clearance. We determined renal plasma flow (RPF), filtration fraction (FF) and total renal vascular resistance (TRVR). Using furosemide, we investigated the role of tubuloglomerular feedback (TGF) for GFR reduction. Using enalapril and the angiotensin II antagonist DUP 753 we investigated the role of angiotensin II for GFR reduction. Six days' application of 0.5 mg/kg b.wt. of OTA i.p. to male Wistar rats leads to RPF reduction from 3.98 +/- 0.18 to 1.97 +/- 0.18 ml/(min.g kidney wet weight) and GFR reduction from 1.08 +/- 0.06 to 0.69 +/- 0.04 ml/(min.g kidney wet weight) (n = 6, P < .05 for both). FF increased to 130% of control and TRVR to 202% of control (n = 6, P < .05 for both). The application of furosemide (30 mg/(h.kg b.wt.) after pretreatment with OTA had no effect on the reduction of GFR indicating that TGF is not involved. Pretreatment with OTA and enalapril [0.5 mg/(d.kg) b.wt.] blunted the effect of OTA alone significantly (GFR only dropped to 88% of control). Pretreatment with OTA and DUP 753 [20 mg/(d.kg) b.wt.] blunted the effect of OTA alone significantly: GFR and RPF only dropped to 89 and 91% of control, respectively. FF and TRVR were no longer different from control. Acute application of DUP 753 (2 mg/kg b.wt. i.v.) after pretreatment with OTA blunted the effect of OTA to a lesser extend. Our conclusions are: 1) Reduction of PAH clearance and of GFR is in part due to reduced RPF. 2) The increase in TRVR is at least in part caused by an increase of the efferent resistance. 3) Activation of the TGF is not involved in GFR reduction. 4) The increase in TRVR and the decrease of GFR are mainly mediated by angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8229758

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity.

Authors:  Joseph L Jilek; Kayla L Frost; Solène Marie; Cassandra M Myers; Michael Goedken; Stephen H Wright; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2021-12-17       Impact factor: 3.579

2.  Thermostability of Ochratoxin A in wheat under two moisture conditions.

Authors:  H Boudra; P Le Bars; J Le Bars
Journal:  Appl Environ Microbiol       Date:  1995-03       Impact factor: 4.792

3.  Molecular mechanism of ochratoxin a transport in the kidney.

Authors:  Naohiko Anzai; Promsuk Jutabha; Hitoshi Endou
Journal:  Toxins (Basel)       Date:  2010-06-09       Impact factor: 4.546

Review 4.  Ochratoxin A: 50 Years of Research.

Authors:  Frantisek Malir; Vladimir Ostry; Annie Pfohl-Leszkowicz; Jan Malir; Jakub Toman
Journal:  Toxins (Basel)       Date:  2016-07-04       Impact factor: 4.546

5.  Ochratoxin A induces ER stress and apoptosis in mesangial cells via a NADPH oxidase-derived reactive oxygen species-mediated calpain activation pathway.

Authors:  Meei-Ling Sheu; Chin-Chang Shen; Yuan-Siao Chen; Chih-Kang Chiang
Journal:  Oncotarget       Date:  2017-03-21

6.  Change of Amino Acid Residues in Idiotypic Nanobodies Enhanced the Sensitivity of Competitive Enzyme Immunoassay for Mycotoxin Ochratoxin A in Cereals.

Authors:  Caixia Zhang; Weiqi Zhang; Xiaoqian Tang; Qi Zhang; Wen Zhang; Peiwu Li
Journal:  Toxins (Basel)       Date:  2020-04-23       Impact factor: 4.546

Review 7.  Metabolites of Microbial Origin with an Impact on Health: Ochratoxin A and Biogenic Amines.

Authors:  Pasquale Russo; Vittorio Capozzi; Giuseppe Spano; Maria R Corbo; Milena Sinigaglia; Antonio Bevilacqua
Journal:  Front Microbiol       Date:  2016-04-08       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.